drugset / Trial / NCT07277452
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
Phase 2
Not yet recruiting
156 enrolled
The First Affiliated Hospital with Nanjing Medical University
Peking University Cancer Hospital & Institute · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. Led by The First Affiliated Hospital with Nanjing Medical University and Peking University Cancer Hospital \& Institute (as leading centers), its main purpose is to evaluate the clinical efficacy and safety of Nimotuzumab combined with nab-paclitaxel plus gemcitabine (AG) in the perioperative treatment of high-risk resectable/borderline resectable pancreatic cancer.
Timeline
- Start
- 2025-12-10
- Primary completion
- 2028-12-10
- Completion
- 2029-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 125 mg/m2 | — |